ALPS Medical Breakthroughs ETF (SBIO)
| Assets | $241.22M |
| Expense Ratio | 0.50% |
| PE Ratio | n/a |
| Shares Out | 3.53M |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| Volume | 31,617 |
| Open | 69.15 |
| Previous Close | 69.51 |
| Day's Range | 67.02 - 69.15 |
| 52-Week Low | 34.66 |
| 52-Week High | 70.85 |
| Beta | 0.74 |
| Holdings | 107 |
| Inception Date | Dec 31, 2014 |
About SBIO
Fund Home PageThe ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is issued by SS&C.
Top 10 Holdings
31.22% of assets| Name | Symbol | Weight |
|---|---|---|
| Crinetics Pharmaceuticals, Inc. | CRNX | 4.57% |
| Apogee Therapeutics, Inc. | APGE | 4.27% |
| CG Oncology, Inc. | CGON | 3.35% |
| Travere Therapeutics, Inc. | TVTX | 3.12% |
| Xenon Pharmaceuticals Inc. | XENE | 2.96% |
| Dianthus Therapeutics, Inc. | DNTH | 2.96% |
| Oruka Therapeutics, Inc. | ORKA | 2.81% |
| ACADIA Pharmaceuticals Inc. | ACAD | 2.55% |
| Edgewise Therapeutics, Inc. | EWTX | 2.35% |
| Definium Therapeutics, Inc. | DFTX | 2.28% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 19, 2024 | $1.17346 | Dec 26, 2024 |
| Dec 21, 2023 | $0.07106 | Dec 27, 2023 |
| Dec 19, 2019 | $0.01585 | Dec 27, 2019 |
| Dec 20, 2018 | $0.7841 | Dec 27, 2018 |
| Dec 21, 2017 | $0.57949 | Dec 28, 2017 |
Performance
SBIO had a total return of 90.38% in the past year, including dividends. Since the fund's inception, the average annual return has been 9.52%.
News
3 Small-Cap ETFs to Watch as Russell 2000 Hits Record
The Russell 2000 closed at a new record high Friday amid continued upwards momentum for several market indexes. That index, with its focus on small-caps, could prove an intriguing source of investing ...
Risk-Wary Family Offices Double Down on Infrastructure
Geopolitical shocks have pushed family offices to rethink nearly every corner of their portfolios. Infrastructure has emerged as the asset class they trust most right now.
Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals
Big Pharma has a $300 billion problem, and biotech developers with promising drugs are becoming the fix. Major drugmakers are spending at a pace not seen since 2019 to replace medicines that will soon...
Biotech Gives SBIO Its Best Month Since 2023
Biotech stocks delivered their best single month since late 2023 in June, carrying the ALPS Medical Breakthroughs ETF (SBIO) to one of the top returns across the ALPS lineup. Key Takeaways: SBIO retur...
June's Top ETFs: Biotech & China Semiconductors Surge
June has been a month full of excitement in the ETF market. While commercial space and AI infrastructure attracted a significant amount of investor attention, biotechnology exposure comprises four out...
CREATOR TV SPORTS™ UNVEILS CREATOR LINEUP FOR INAUGURAL "CREATOR PICKLEBALL TOUR" AT VIDCON ANAHEIM
NichLmao, Peet Montzingo, DangMattSmith, Merrick Hanna and more to compete in a 16-player tournament produced by Creator TV®, set to premiere on streaming this summer. LOS ANGELES, June 15, 2026 /PRNe...
Advacam & Vector Space Biosciences sign Letter of Intent (LOI) to Develop AI Models & CubeSat Payloads for the Space Industry
LA JOLLA, Calif.--(BUSINESS WIRE)---- $SBIO #Advacam--Advacam, provider of radiation detectors that map radiation aboard the International Space Station (ISS) and Vector Space Biosciences (crypto symb...
Vector Space Biosciences (SBIO) Is Now Available for Trading on LBank Exchange
Road Town, Virgin Islands--(Newsfile Corp. - September 24, 2023) - LBank Exchange, a global digital asset trading platform, listed Vector Space Biosciences (SBIO) on September 15, 2023. For all users ...